Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

VJVirtual | Arnon Nagler: transplantation during the COVID-19 pandemic

Arnon Nagler • 31 Mar 2020
General Multiple Myeloma

In these unprecedented times, Arnon Nagler, MD, MSc, Sheba Medical Center, Tel-Aviv, Israel, explains how COVID-19 is impacting transplantation patients and gives his advice to peers on how these new challenges can be met. Prof. Nagler goes on to touch on the management of multiple myeloma during this difficult time. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Arnon Nagler

Evaluating the impact of donor age on alloSCT outcomes in patients with secondary AML in CR1 2:01
Evaluating the impact of donor age on alloSCT outcomes in patients with secondary AML in CR1
Arnon Nagler • 6 Dec 2025
Transplanting patients with advanced AML 3:07
Transplanting patients with advanced AML
Arnon Nagler • 30 Mar 2025
Bone marrow versus mobilized peripheral blood grafts for haploidentical transplant in secondary AML 1:42
Bone marrow versus mobilized peripheral blood grafts for haploidentical transplant in secondary AML
Arnon Nagler • 30 Mar 2025
Is there a preferable donor for alloSCT in secondary AML in first complete remission? 2:23
Is there a preferable donor for alloSCT in secondary AML in first complete remission?
Arnon Nagler • 30 Mar 2025

Related Videos

Press briefing: results from the ACCESS trial 10:36
Press briefing: results from the ACCESS trial
Antonio Jimenez-Jimenez • 7 Dec 2025
Initial results from MajesTEC-3: Tec-Dara versus DPd/DVd in patients with R/R multiple myeloma 3:53
Initial results from MajesTEC-3: Tec-Dara versus DPd/DVd in patients with R/R multiple myeloma
Luciano Costa • 16 Dec 2025
Belantamab mafodotin in functional high-risk RRMM: subgroup analysis of DREAMM-7 and DREAMM-8 4:02
Belantamab mafodotin in functional high-risk RRMM: subgroup analysis of DREAMM-7 and DREAMM-8
Meral Beksac • 10 Dec 2025
Incidence and risk factors for infections in NDMM treated with modern induction regimens 1:54
Incidence and risk factors for infections in NDMM treated with modern induction regimens
Efstathios Kastritis • 7 Dec 2025
The content of VJHemOnc is intended for healthcare professionals